Another study in breast cancer cells has shown that PART1 silencing improves the sensitivity of these cells to cisplatin, promotes cell apoptosis, and decreases expression proteins contributing in drug resistance (Lou et al., 2020). This evidence concerns the gene PART1 and breast carcinoma.